Skip to main content

Vyondys 53 Disease Interactions

There are 2 disease interactions with Vyondys 53 (golodirsen).

Moderate

Antisense oligonucleotides (applies to Vyondys 53) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Renal toxicity has been observed in animals receiving antisense oligonucleotides including golodirsen, casimersen, and viltolarsen. Renal toxicity has not been observed in clinical studies with these agents, but clinical experience is limited, and renal toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured prior to therapy with urine dipstick repeated monthly and serum cystatin C and UPCR repeated every 3 months during therapy. The glomerular filtration rate may be measured using an exogenous filtration marker prior to therapy. For patients with Duchenne muscular dystrophy (DMD), creatinine may not be a reliable measure of kidney function due to a reduced skeletal muscle mass. If persistent increases in serum cystatin C or proteinuria are detected, the patient should be referred to a nephrologist for further evaluation. Patients with known renal function impairment should be closely monitored during treatment.

References

  1. (2020) "Product Information. Vyondys 53 (golodirsen)." Sarepta Therapeutics
  2. (2020) "Product Information. Viltepso (viltolarsen)." NS Pharma
  3. (2021) "Product Information. Amondys 45 (casimersen)." Sarepta Therapeutics
Moderate

Golodirsen (applies to Vyondys 53) hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

Golodirsen has not been studied in patients with hepatic impairment. Caution is advised.

References

  1. (2020) "Product Information. Vyondys 53 (golodirsen)." Sarepta Therapeutics

Vyondys 53 drug interactions

There are 3 drug interactions with Vyondys 53 (golodirsen).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer